NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/03/2026 12:49
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization15.27 mln
Float2.38 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
8
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
ROE
-336
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Cadrenal Therapeutics is a Florida-based pharmaceutical company working to bring a new blood-thinning medication called Tecarfarin to patients with serious heart and circulatory conditions. Unlike many existing treatments, Tecarfarin is taken by mouth and can be reversed if needed, making it a promising option for people living with mechanical heart pumps, advanced kidney disease, or conditions that cause dangerous blood clotting. The company has partnered with Abbott Global Enterprises to study how well Tecarfarin works in patients who rely on mechanical heart pump devices.
